BRPI0512060A - compostos orgánicos - Google Patents

compostos orgánicos

Info

Publication number
BRPI0512060A
BRPI0512060A BRPI0512060-8A BRPI0512060A BRPI0512060A BR PI0512060 A BRPI0512060 A BR PI0512060A BR PI0512060 A BRPI0512060 A BR PI0512060A BR PI0512060 A BRPI0512060 A BR PI0512060A
Authority
BR
Brazil
Prior art keywords
organic compounds
compounds
nep
pharmaceuticals
processes
Prior art date
Application number
BRPI0512060-8A
Other languages
English (en)
Inventor
Kamlesh Bala
Catherine Leblanc
David Andrew Sandham
Katharine Louise Turner
Simon James Watson
Lyndon Nigel Brown
Brian Cox
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413619A external-priority patent/GB0413619D0/en
Priority claimed from GB0507693A external-priority patent/GB0507693D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0512060A publication Critical patent/BRPI0512060A/pt
Publication of BRPI0512060B1 publication Critical patent/BRPI0512060B1/pt
Publication of BRPI0512060B8 publication Critical patent/BRPI0512060B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)

Abstract

COMPOSTOS ORGáNICOS. A presente invenção refere-se a compostos de fórmula (l), em forma livre ou de sal, em que R¬ ¹¬,R¬ ²¬, R¬ ³¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, Q, W, X, m, n e p são tais como descritos no relatório descritivo, processos para a preparação deles, e o seu uso como produtos farmacêuticos.
BRPI0512060A 2004-06-17 2005-06-16 compostos orgânicos, composições farmacêuticas compreendendo os mesmos, bem como uso e processo de preparação dos referidos compostos BRPI0512060B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0413619.8 2004-06-17
GB0413619A GB0413619D0 (en) 2004-06-17 2004-06-17 Organic compounds
GB0507693.0 2005-04-15
GB0507693A GB0507693D0 (en) 2005-04-15 2005-04-15 Organic compounds
PCT/EP2005/006493 WO2005123731A2 (en) 2004-06-17 2005-06-16 Pyrrolopyridine derivatives and their use as crth2 antagonists

Publications (3)

Publication Number Publication Date
BRPI0512060A true BRPI0512060A (pt) 2008-02-06
BRPI0512060B1 BRPI0512060B1 (pt) 2018-08-07
BRPI0512060B8 BRPI0512060B8 (pt) 2021-05-25

Family

ID=35510318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512060A BRPI0512060B8 (pt) 2004-06-17 2005-06-16 compostos orgânicos, composições farmacêuticas compreendendo os mesmos, bem como uso e processo de preparação dos referidos compostos

Country Status (29)

Country Link
US (5) US7666878B2 (pt)
EP (1) EP1761529B3 (pt)
JP (1) JP4886680B2 (pt)
KR (1) KR101183330B1 (pt)
AR (1) AR049443A1 (pt)
AT (1) ATE378338T1 (pt)
AU (1) AU2005254681B2 (pt)
BR (1) BRPI0512060B8 (pt)
CA (1) CA2569125C (pt)
CY (1) CY1107851T1 (pt)
DE (1) DE602005003365T3 (pt)
DK (1) DK1761529T3 (pt)
EC (1) ECSP067077A (pt)
ES (1) ES2294717T7 (pt)
HK (1) HK1103730A1 (pt)
HR (1) HRP20080022T4 (pt)
IL (1) IL179604A (pt)
MA (1) MA28666B1 (pt)
MX (1) MXPA06014694A (pt)
MY (1) MY144903A (pt)
NO (1) NO338319B1 (pt)
NZ (1) NZ551439A (pt)
PE (1) PE20060301A1 (pt)
PL (1) PL1761529T6 (pt)
PT (1) PT1761529E (pt)
RS (1) RS50552B (pt)
RU (1) RU2379309C2 (pt)
TW (1) TWI352702B (pt)
WO (1) WO2005123731A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
PL1986633T3 (pl) 2006-02-10 2015-01-30 Summit Oxford Ltd Leczenie dystrofii mięśniowej Duchenne'a
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
RU2448092C2 (ru) 2006-08-07 2012-04-20 Актелион Фармасьютиклз Лтд Производные (3-амино-1,2,3,4-тетрагидро-9н-карбазол-9-ил)уксусной кислоты
EP2170396B1 (en) * 2007-08-03 2016-12-21 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
US8101645B2 (en) 2008-02-15 2012-01-24 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
LT2318006T (lt) 2008-08-15 2017-01-10 Nivalis Therapeutics, Inc. Nauji s-nitrozoglutationo reduktazės pirolo inhibitoriai, kaip terapiniai agentai
DK2315590T3 (da) 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
WO2010019905A1 (en) 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
AR080703A1 (es) 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
BR112013015397A2 (pt) * 2010-12-23 2016-09-20 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9725442B2 (en) 2011-10-25 2017-08-08 Shionogi & Co., Ltd. Heterocyclic derivative having PGD2 receptor antagonist activity
BR112014014558A8 (pt) 2011-12-16 2017-07-04 Atopix Therapeutics Ltd composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
PL3119779T3 (pl) 2014-03-17 2019-01-31 Idorsia Pharmaceuticals Ltd Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2
RU2016140708A (ru) 2014-03-18 2018-04-18 Идорсиа Фармасьютиклз Лтд Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
MX2017001554A (es) 2014-08-04 2017-07-24 Nuevolution As Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
JP6703090B2 (ja) 2015-07-23 2020-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体アンタゴニストに対する応答に関連した遺伝的マーカー
KR20180053345A (ko) 2015-09-15 2018-05-21 이도르시아 파마슈티컬스 리미티드 결정질 형태
KR102279993B1 (ko) 2015-09-23 2021-07-21 엑스더블유파마 리미티드 감마-하이드록시부티르산의 전구체 및 이의 조성물 및 용도
HUE049566T2 (hu) * 2015-09-29 2020-09-28 Novartis Ag Eljárás 1-(4-metánszulfonil-2-trifluormetil-benzil)-2-metil-1H-pirrolo- [2,3-B]piridin-3-il-ecetsav elõállítására
WO2017210261A1 (en) * 2016-05-31 2017-12-07 Concert Pharmaceuticals, Inc. Deuterated fevipiprant
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3730487B1 (en) 2016-06-13 2022-04-27 Gilead Sciences, Inc. Azetidine derivatives as fxr (nr1h4) modulators
CN106188040B (zh) * 2016-06-28 2018-03-23 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
US11524958B2 (en) 2016-07-21 2022-12-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound as CRTH2 inhibitor
KR20190126920A (ko) 2017-03-28 2019-11-12 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
JP6991239B2 (ja) 2017-03-30 2022-01-12 エックスダブリューファルマ リミテッド 二環式ヘテロアリール誘導体ならびにその調製および使用
JOP20190223A1 (ar) 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
KR20240033119A (ko) 2017-06-30 2024-03-12 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
WO2019011337A1 (zh) * 2017-07-14 2019-01-17 苏州科睿思制药有限公司 Qaw-039的晶型及其制备方法和用途
WO2019130166A1 (en) * 2017-12-26 2019-07-04 Mankind Pharma Ltd. Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
AU2019209725B2 (en) 2018-01-19 2023-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form of indole derivative and preparation method and use thereof
CN110467612B (zh) * 2018-05-09 2020-09-25 新发药业有限公司 一种前列腺素d2受体抑制剂化合物的简便制备方法
WO2020062251A1 (en) 2018-09-30 2020-04-02 Xw Laboratories, Inc. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
EA202191566A1 (ru) 2019-01-15 2021-11-01 Джилид Сайенсиз, Инк. Соединения, модулирующие fxr (nr1h4)
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
CA3162919A1 (en) 2019-12-20 2021-06-24 XWPharma Ltd. Methods of synthesizing 4-valyloxybutyric acid
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
JP2023537192A (ja) 2020-06-18 2023-08-31 エックスダブリューファーマ リミテッド 水溶性医薬品有効成分の医薬造粒物
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US11510892B2 (en) 2021-03-19 2022-11-29 XWPharma Ltd. Pharmacokinetics of combined release formulations of a γ-hydroxybutyric acid derivative

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US5212195A (en) 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1995034563A1 (en) 1994-06-16 1995-12-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
EP1424325A4 (en) 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2423190A1 (en) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20140309254A1 (en) 2014-10-16
US9169251B2 (en) 2015-10-27
MA28666B1 (fr) 2007-06-01
AR049443A1 (es) 2006-08-02
WO2005123731A2 (en) 2005-12-29
CA2569125C (en) 2013-01-08
DE602005003365D1 (de) 2011-01-05
TW200617009A (en) 2006-06-01
US20100204225A1 (en) 2010-08-12
KR101183330B1 (ko) 2012-09-17
CY1107851T1 (el) 2013-06-19
HK1103730A1 (en) 2007-12-28
IL179604A0 (en) 2007-05-15
JP4886680B2 (ja) 2012-02-29
TWI352702B (en) 2011-11-21
US7666878B2 (en) 2010-02-23
WO2005123731A3 (en) 2006-05-04
PL1761529T6 (pl) 2011-11-30
HRP20080022T3 (en) 2008-02-29
AU2005254681B2 (en) 2009-01-29
ES2294717T3 (es) 2008-04-01
DE602005003365T3 (de) 2012-08-30
ATE378338T1 (de) 2007-11-15
RU2379309C2 (ru) 2010-01-20
US20130267518A1 (en) 2013-10-10
DE602005003365T2 (de) 2008-09-11
AU2005254681A1 (en) 2005-12-29
HRP20080022T4 (hr) 2011-10-31
RU2007101277A (ru) 2008-07-27
ES2294717T7 (es) 2012-06-14
BRPI0512060B8 (pt) 2021-05-25
US8791256B2 (en) 2014-07-29
PE20060301A1 (es) 2006-05-18
DK1761529T3 (da) 2008-03-25
EP1761529B1 (en) 2007-11-14
KR20070032694A (ko) 2007-03-22
CA2569125A1 (en) 2005-12-29
EP1761529B3 (en) 2011-06-15
NO338319B1 (no) 2016-08-08
US8455645B2 (en) 2013-06-04
ECSP067077A (es) 2007-01-26
PL1761529T3 (pl) 2008-04-30
MXPA06014694A (es) 2007-02-12
NO20070323L (no) 2007-03-12
US20080114022A1 (en) 2008-05-15
US20100210610A1 (en) 2010-08-19
PT1761529E (pt) 2008-02-11
RS50552B (sr) 2010-05-07
BRPI0512060B1 (pt) 2018-08-07
MY144903A (en) 2011-11-30
US8470848B2 (en) 2013-06-25
JP2008502638A (ja) 2008-01-31
NZ551439A (en) 2009-09-25
EP1761529A2 (en) 2007-03-14
IL179604A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
BRPI0512060A (pt) compostos orgánicos
BRPI0508969A (pt) compostos orgánicos
BRPI0510412A (pt) compostos orgánicos
NO20071880L (no) Diagnostic Compounds
TW200732335A (en) Organic compounds
BRPI0510410A (pt) compostos orgánicos
BRPI0518607A2 (pt) derivados de pirrol tendo atividade antagonista de receptor crth2
BRPI0511621A (pt) compostos orgánicos
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
BRPI0606636A2 (pt) compostos macrocìclicos úteis como inibidores de bace
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
TW200732337A (en) Organic compounds
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR0316375A (pt) Diazinopirimidinas
UY30206A1 (es) Derivados de diamina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BRPI0518752A2 (pt) 1-alquinil-2-arilàxi-alquil-amidas e uso do mesmo como fungicidas
BRPI0511885A (pt) derivados de cromona úteis como antagonistas de vanilóide
BRPI0611863A2 (pt) composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
BRPI0410238A (pt) compostos orgánicos
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.